{"id":51135,"date":"2025-12-17T19:20:27","date_gmt":"2025-12-17T11:20:27","guid":{"rendered":"https:\/\/flcube.com\/?p=51135"},"modified":"2025-12-17T19:20:30","modified_gmt":"2025-12-17T11:20:30","slug":"aficamten-wins-china-approval-as-hcm-drug-in-global-first-for-sanofi","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51135","title":{"rendered":"Aficamten Wins China Approval as HCM Drug in Global First for Sanofi"},"content":{"rendered":"\n

Sanofi<\/strong> (NASDAQ: SNY<\/a>) announced that aficamten<\/strong>, a second\u2011generation cardiac myosin inhibitor, received marketing approval from China\u2019s National Medical Products Administration (NMPA)<\/strong> for adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM)<\/strong> (NYHA Class\u202fII\u2011III). The approval marks a \u201cGlobal First\u201d<\/strong> launch, with China authorizing the drug ahead of the US, EU, and other regions.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Approval Date<\/strong><\/td>17\u202fDec\u202f2025<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Product<\/strong><\/td>Aficamten tablets<\/td><\/tr>
Indication<\/strong><\/td>Symptomatic obstructive HCM (NYHA Class\u202fII\u2011III)<\/td><\/tr>
Innovation<\/strong><\/td>First\u2011in\u2011class second\u2011generation cardiac myosin inhibitor<\/strong><\/td><\/tr>
Global Status<\/strong><\/td>China approval precedes US, EU, and other regions<\/td><\/tr>
Guideline Support<\/strong><\/td>Recommended in 2025 Chinese Guidelines for Comprehensive Management of Cardiomyopathy<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism<\/h2>\n\n\n\n
Attribute<\/th>Aficamten<\/th>Competitive Context<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Cardiac myosin inhibitor<\/strong>; blocks force\u2011producing cross\u2011bridge formation<\/td>Directly reduces myocardial hypercontractility<\/td><\/tr>
Pharmacology<\/strong><\/td>Half\u2011life 3\u20134 days<\/strong>; optimal dose reached in 8 weeks<\/strong><\/td>Faster titration vs. first\u2011generation agents (e.g., mavacamten)<\/td><\/tr>
Developer<\/strong><\/td>Discovered and developed globally by Cytokinetics<\/strong><\/td>Licensed to Jixing Pharma (July\u202f2020), acquired by Sanofi (Dec\u202f2024)<\/td><\/tr>
Administration<\/strong><\/td>Oral tablets (patient\u2011convenient)<\/td>Addresses compliance barriers of injectable therapies<\/td><\/tr>
Differentiation<\/strong><\/td>Best\u2011in\u2011class potential<\/strong> with improved PK\/PD profile<\/td>Lower off\u2011target effects, enhanced safety margin<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development & Commercialization Chain<\/h2>\n\n\n\n
Date<\/th>Event<\/th><\/tr><\/thead>
July\u202f2020<\/strong><\/td>Jixing Pharma licenses aficamten from Cytokinetics for Greater China<\/td><\/tr>
Dec\u202f2024<\/strong><\/td>Sanofi acquires Jixing\u2019s exclusive rights for aficamten in Greater China<\/td><\/tr>
Dec\u202f2025<\/strong><\/td>NMPA approves aficamten for obstructive HCM (Global First launch)<\/td><\/tr>
Expected US\/EU<\/strong><\/td>Regulatory filings under review; approvals anticipated 2026\u20112027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
China HCM Prevalence<\/strong><\/td>~300,000 patients (2025)<\/td>~70% have obstructive phenotype<\/td><\/tr>
China HCM Market<\/strong><\/td>\u00a52\u20113\u202fbillion<\/strong> (\u2248\u202fUS$280\u2011420\u202fM)<\/td>Growing diagnosis rate; limited targeted therapies<\/td><\/tr>
Aficamten Peak Sales<\/strong><\/td>\u00a51.5\u20112.0\u202fbillion<\/strong> (\u2248\u202fUS$210\u2011280\u202fM) by 2030<\/td>40\u201150% share of eligible obstructive HCM patients<\/td><\/tr>
Global HCM Market<\/strong><\/td>$1.2\u202fbillion (2025)<\/td>Projected $2.5\u202fbillion by 2030 with new agents<\/td><\/tr>
Pricing Strategy<\/strong><\/td>Premium oral therapy pricing<\/td>Justified by efficacy and faster titration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n